{"id":"NCT00326118","sponsor":"GlaxoSmithKline","briefTitle":"Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.","officialTitle":"Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix™, Versus MenC-CRM197 Vaccine With Hiberix™ & Priorix™ in Toddlers Primed With Hib But Not MenC & to Evaluate Persistence up to 5 Years After Vaccination.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06-01","primaryCompletion":"2007-11-01","completion":"2007-11-06","firstPosted":"2006-05-16","resultsPosted":"2009-10-23","lastUpdate":"2018-08-24"},"enrollment":433,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"interventions":[{"type":"BIOLOGICAL","name":"Haemophilus influenzae type b and meningococcal serogroup C (vaccine)","otherNames":["Hib-MenC","Menitorix™"]},{"type":"BIOLOGICAL","name":"Priorix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Hiberix™","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningitec™","otherNames":[]}],"arms":[{"label":"Meningitec + Hiberix Group","type":"ACTIVE_COMPARATOR"},{"label":"Menitorix Group","type":"EXPERIMENTAL"}],"summary":"The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year of life to subjects primed in infancy with a Hib vaccine, but not with a meningococcal serogroup C vaccine, versus commercially available Hib and MenC vaccines.\n\nIn the extension phase, at Years 1, 2, 3, 4 \\& 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","primaryOutcome":{"measure":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)","timeFrame":"1 month after vaccination","effectByArm":[{"arm":"Menitorix Group","deltaMin":292,"sd":null},{"arm":"Meningitec + Hiberix Group","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":7,"countries":["Australia"]},"refs":{"pmids":["21068692","23080288"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":324},"commonTop":["Irritability","Redness","Drowsiness","Loss of appetite","Pain"]}}